Company Filing History:
1 out of 832,891 Years Active: 2012
Title: Richard Schlenk: Innovator in Acute Myeloid Leukemia Treatment
Introduction
Richard Schlenk is a notable inventor based in Ulm, Germany. He has made significant contributions to the field of medical science, particularly in the treatment of acute myeloid leukemia (AML). His innovative approach focuses on the use of all-trans retinoic acid for developing pharmaceutical compositions aimed at treating specific types of AML.
Latest Patents
Richard Schlenk holds 1 patent related to his groundbreaking work. His patent, titled "Diagnostic assay for the specific treatment of acute myeloid leukemia," outlines a method for selecting patients based on the physiological concentration of MN1. This invention emphasizes the importance of determining the MN1 level in total blood cells or bone marrow cells to tailor treatments effectively.
Career Highlights
Throughout his career, Richard Schlenk has dedicated himself to advancing cancer treatment methodologies. His research has provided valuable insights into the specific needs of non-M3 acute myeloid leukemia patients. By focusing on the transcription level of MN1, he has contributed to more personalized and effective treatment options.
Collaborations
Richard Schlenk has worked alongside esteemed colleagues, including Michael Heuser and Arnold Ganser. Their collaborative efforts have furthered research in the field of hematology and oncology, enhancing the understanding of acute myeloid leukemia.
Conclusion
In summary, Richard Schlenk is a prominent inventor whose work in the treatment of acute myeloid leukemia has the potential to change patient outcomes significantly. His innovative patent and collaborative research efforts highlight his commitment to advancing medical science.